Carmichael Hill & Associates, Inc. Avadel Pharmaceuticals PLC Call Options Transaction History

Carmichael Hill & Associates, Inc.

  • $279 Million
  • Q3 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2023

Aug 04, 2023
BUY
$8.48 - $16.48 $16,960 - $32,960
2,000 New
2,000 $32,000
Q4 2021

Jan 31, 2022
SELL
$7.34 - $11.18 $7,340 - $11,180
-1,000 Reduced 33.33%
2,000 $16,000
Q1 2021

Apr 28, 2021
BUY
$6.61 - $10.07 $19,830 - $30,210
3,000 New
3,000 $27,000

Others Institutions Holding AVDL

# of Institutions
8
Shares Held
1.07M
Call Options Held
0
Put Options Held
0
View Full List

About AVADEL PHARMACEUTICALS PLC

AVDL Quotes by TradingView
  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $650M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Carmichael Hill & Associates, Inc. Portfolio

Follow Carmichael Hill & Associates, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Carmichael Hill & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Carmichael Hill & Associates, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email